{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-042789","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.060757+00:00","generated_at":"2026-06-04T01:01:16.838603+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acrivon nets ~$130M in PIPE; shares at $8.50, pre-funded warrants for 7.1M shares","bullets":["Gross proceeds ~$130M from 8.235M shares at $8.50/share and 7.06M pre-funded warrants at $8.499/warrant.","Pre-funded warrants exercisable at $0.001/share, immediately exercisable, no expiration.","Investors include RA Capital, Perceptive Advisors, Paradigm BioCapital, Surveyor Capital, Sands Capital, Acorn Bioventures.","Proceeds to fund ACR-368 registrational trials, ACR-2316, cell cycle program, AP3 platform, AI/ML; cash runway into H2 2026.","Closing expected April 11, 2024; Jefferies acted as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-042789","json":"https://secwatch.observer/filing/0000950170-24-042789.json","markdown":"https://secwatch.observer/filing/0000950170-24-042789.md","text":"https://secwatch.observer/filing/0000950170-24-042789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/0000950170-24-042789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017024042789/acrv-20240408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:01:16.838603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}